LIFECORE BIOMEDICAL, INC. \DE\

For the period ended Mar 31, 2026. Filed May 6, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 6, 2026

LFCR$6.37+0.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Revenue recognition

Revenue recognition

The following tables present disaggregated revenues:

	Three months ended
	March 31,2026	February 23,2025
CDMO	$15,775	$20,789
HA manufacturing	7,418	14,365
Total	$23,193	$35,154
Revenues recognized over time	$4,223	$5,505
Revenues recognized at a point in time	18,970	29,649
Total	$23,193	$35,154

Duringthe three months ended March 31, 2026, the Company had revenue concentrations of 10% or greater from two customers, with those customers comprising 39% and 22% of revenue. During the three months ended February 23, 2025, the Company had revenue concentrations of 10% or greater from two customers, with those customers comprising 54% and 18% of revenue.

The following table presents changes in contract assets and liabilities:

	Contract assets	Contract liabilities
Balance at December 31, 2025	$7,655	$(8,660)
Changes to the beginning balance arising from:
Amounts billed as accounts receivable as the result of rights to consideration becoming unconditional	(5,067)	—
Recognition of revenue as the result of performance obligations satisfied	—	3,109
Net change to contract balances recognized after the comparative balance sheet date due to amounts billed, recognition of revenue, changes in estimate, and interest from significant financing component	4,861	(313)
Balance at March 31, 2026	$7,449	$(5,864)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.